Oseltamivir

Introduction Overview

Generic Name

oseltamivir

Brand Name

Tamiflu

Dosage Form

Oral capsule and oral suspension

Drug Class

Neuraminidase inhibitors

Pharmacokinetics

Absorption:
Oseltamivir is rapidly absorbed from the gastrointestinal tract following oral administration. After ingestion, the prodrug oseltamivir phosphate undergoes efficient and almost complete absorption, with peak plasma concentrations of its active metabolite, oseltamivir carboxylate, observed typically within 2 to 3 hours. The oral bioavailability of oseltamivir is approximately 80%, and absorption is not significantly affected by concurrent food intake, although intake of food may mitigate gastrointestinal side effects.

Distribution:
Oseltamivir carboxylate is widely distributed throughout the body’s extracellular fluids. It demonstrates low plasma protein binding, generally less than 3%, facilitating its extensive tissue penetration. The volume of distribution averages around 23 to 26 liters. The active metabolite effectively reaches respiratory tract tissues, which is crucial for its antiviral action against influenza viruses in the respiratory epithelium.

Metabolism:
Oseltamivir phosphate is a prodrug that is converted almost completely to its active form, oseltamivir carboxylate, by hepatic esterases primarily in the liver. It is not significantly metabolized by cytochrome P450 enzymes, which reduces the potential for metabolic drug-drug interactions. The conversion to the active metabolite is rapid and efficient, leading to predictable pharmacokinetics.

Elimination:
The principal route of elimination for oseltamivir carboxylate is renal excretion via glomerular filtration and tubular secretion. Approximately 99% of the active metabolite is eliminated unchanged in the urine. The plasma elimination half-life of oseltamivir carboxylate is approximately 6 to 10 hours in healthy adults. Renal impairment markedly reduces clearance, necessitating dosage adjustments in patients with varying degrees of renal dysfunction. There is minimal fecal excretion. Studies demonstrate that oseltamivir carboxylate plasma concentrations correlate with antiviral efficacy and safety.

Pharmacokinetic parameters are consistent across age groups, with adjustments recommended for pediatric and elderly patients based on renal function. Overall, the rapid absorption, efficient conversion to the active metabolite, and predominant renal clearance define oseltamivir’s pharmacokinetic profile, supporting its dosing regimen for influenza treatment and prophylaxis.

Dosage Forms

Available Dosage Forms:
Tamiflu is available in two primary oral formulations:
- Capsules containing 30 mg, 45 mg, and 75 mg of oseltamivir phosphate.
- Oral suspension (liquid) available as a powder for reconstitution with concentrations of 6 mg/mL after preparation.

Dosages for Adults and Adolescents:
For treatment of influenza in individuals aged 13 years and older, the standard dose is 75 mg taken orally twice daily for 5 days. For prophylaxis, the recommended dose is 75 mg taken once daily for at least 10 days or longer during community outbreaks.

Specific Patient Populations:
- Pediatrics: Treatment doses vary by weight, for example, children weighing 15 kg or less receive 30 mg twice daily, whereas larger children receive proportionally higher doses up to adult doses. Prophylaxis dosing is once daily for approximately 10 days.
- Renal impairment: Dosage adjustments are necessary in patients with creatinine clearance less than 60 mL/min. For example, patients with creatinine clearance 10 to 30 mL/min are often prescribed 75 mg every other day.
- Elderly: No specific dose adjustment is required unless renal impairment is present.
- Pregnant and breastfeeding women: Usual dosing applies, but careful clinical judgment is advised.

Clinicians should follow detailed dosing tables based on weight and renal function as specified in the prescribing information to ensure therapeutic efficacy and safety.

Mechanism Of Action

Oseltamivir, the active ingredient in Tamiflu, functions as a selective inhibitor of the influenza virus neuraminidase enzyme. Neuraminidase is an essential viral surface glycoprotein that facilitates the release of newly formed viral particles from infected host cells. By inhibiting this enzyme, oseltamivir effectively prevents progeny virions from detaching and spreading to uninfected cells within the respiratory tract.

At the molecular level, oseltamivir carboxylate competitively binds to the active site of neuraminidase, mimicking its natural substrate, sialic acid. This binding leads to a blockade of the enzymatic cleavage of sialic acid residues from host cell receptors, thereby halting viral replication and propagation.

Inhibition of neuraminidase reduces viral dissemination and decreases the severity and duration of influenza symptoms. Importantly, oseltamivir shows activity against both influenza A and B virus types, affecting multiple strains and subtypes, including seasonal and certain pandemic strains.

Clinical studies have demonstrated that early administration of oseltamivir within 48 hours of symptom onset leads to a statistically significant reduction in illness duration. Comparative analyses with other neuraminidase inhibitors highlight oseltamivir’s favorable oral bioavailability and tolerability, supporting its widespread clinical use. Ongoing research explores combination therapies and resistance patterns to optimize influenza management.

Pharmacological Actions

Selective inhibition of influenza virus neuraminidase enzyme.
Prevention of viral progeny release from infected host cells.
Reduction of viral replication and spread in respiratory epithelium.
Effective against influenza A and B virus types.
Prophylactic activity to prevent influenza infection in exposed individuals.
Decreases severity and duration of influenza symptoms.
Oral bioavailability enabling ease of administration.
Minimal cytochrome P450 interactions enhancing drug safety.
Rapid onset of antiviral action post-administration.
Favorable pharmacokinetics supporting twice-daily dosing for treatment.
Clinically proven to shorten illness duration by 1 to 2 days.
Potential to reduce influenza-related complications when administered early.
Useful in both outpatient and inpatient influenza management.
Safety profile suitable for use in pediatric and adult populations.
Does not interfere with influenza vaccination efficacy if appropriately timed.

Therapeutic Or Clinical Uses

Treatment of acute uncomplicated influenza A and B virus infections in patients aged 1 year and older presenting within 48 hours of symptom onset.
Prophylaxis of influenza in exposed individuals, including household contacts and community outbreaks.
Reduction in duration and severity of influenza symptoms.
Decreased risk of influenza-associated complications like bronchitis and pneumonia when administered promptly.
Use in high-risk populations including elderly, immunocompromised, and those with chronic medical conditions.
Potential use in hospitalized patients with influenza under clinical guidance.
Adjunct therapy during influenza epidemics and pandemics.
Prevention of influenza transmission in closed settings such as nursing homes and schools.
Use in children aged 1 year and older for both treatment and prevention.
Consideration in pregnant women after risk-benefit evaluation in influenza season.
Management of influenza in patients unable to receive influenza vaccination.
Alternative antiviral option for patients resistant or intolerant to other neuraminidase inhibitors.
Use to mitigate influenza outbreaks in healthcare facilities.
Supportive therapy combined with symptom management for influenza.
Potential investigational role for novel influenza strains pending susceptibility testing.

Side Or Adverse Effects

Nausea and vomiting, more commonly occurring during initial doses.
Headache, reported in multiple clinical trials with mild intensity.
Abdominal pain and discomfort.
Rare cases of allergic reactions including urticaria and angioedema.
Neuropsychiatric events such as confusion, delirium, hallucinations, and unusual behavior, predominantly reported in pediatric populations.
Fatigue and dizziness.
Diarrhea.
Skin reactions including rash and, rarely, severe erythema multiforme or Stevens-Johnson syndrome.
Transient elevations in liver enzymes reported in some patients.
Bronchitis or sinusitis as part of flu symptoms or adverse effects.
Very rare reports of seizures, especially in patients with underlying neurological disorders.
Potential hypersensitivity or anaphylactic reactions.
Injection site reactions are not applicable as drug is oral but gastrointestinal symptoms predominate.
Side effects generally mild to moderate and self-limited.
Monitoring required for psychiatric symptoms especially in children and adolescents.

Precautions

Use with caution in patients with renal impairment; dosage adjustment necessary based on creatinine clearance.
Patients with a history of neuropsychiatric disorders should be monitored closely during treatment.
Inform healthcare provider of any previous allergic reactions to oseltamivir or other antiviral agents.
Use caution when administering to patients with chronic medical conditions such as heart or lung disease.
Not a substitute for annual influenza vaccination; patients should continue to receive the flu vaccine.
Avoid use for treatment in children younger than 2 weeks old; prophylactic use may be considered from 1 year of age.
Pregnant and breastfeeding women should weigh potential benefits against unknown risks; consultation with healthcare provider is essential.
Do not administer nasal influenza vaccine (FluMist) within 48 hours before or after oseltamivir use due to possible interference.
Ensure adherence to prescribed duration of therapy to prevent viral resistance and treatment failure.
Patients should be warned about possible gastrointestinal side effects and advised to take medication with food if needed.
Monitor for signs of hypersensitivity or severe skin reactions.
Consider underlying causes if neuropsychiatric symptoms develop during therapy.
Use in immunocompromised individuals requires careful clinical judgment due to altered viral kinetics.
Educate patients on the importance of early treatment initiation within 48 hours of symptom onset.
Regularly assess renal function in elderly patients receiving Tamiflu.

Warnings

Tamiflu is effective only if started within 48 hours after the onset of influenza symptoms.
Not effective for treatment of the common cold or other non-influenza viral infections.
Potential for neuropsychiatric adverse events, particularly in pediatric patients, including sudden confusion and hallucinations; close monitoring advised.
Risk of allergic reactions including anaphylaxis and serious skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis.
Should not be used as a substitute for annual influenza vaccination.
Concomitant use with live attenuated influenza vaccine (nasal spray) may reduce vaccine effectiveness and is contraindicated within 2 weeks before or after Tamiflu administration.
Dose adjustment required in patients with renal impairment to prevent accumulation and toxicity.
Overdose or misuse may cause serious adverse events; seek immediate medical attention in case of overdose.
May cause gastrointestinal disturbances which can lead to dehydration if persistent.
Patients should complete the full course of therapy even if symptoms improve to reduce resistance emergence.
Safety and efficacy not established in infants under 1 year for flu prevention and under 2 weeks for flu treatment.
Use cautiously in patients with a history of convulsions or seizures.
Post-marketing reports indicate rare psychiatric symptoms; causality remains uncertain but warrants awareness.
Discontinue and seek medical attention if severe skin or hypersensitivity reactions develop.
Not recommended for use in patients with hereditary fructose intolerance due to excipient content.

Contraindication

Known hypersensitivity to oseltamivir phosphate or any component of the formulation.
History of severe allergic reaction to any neuraminidase inhibitor.
Use in children younger than 2 weeks old for treatment is contraindicated.
Concomitant use with live attenuated influenza virus vaccine nasal spray (FluMist) within 2 weeks before or after Tamiflu administration.
Patients with hereditary fructose intolerance should avoid Tamiflu oral suspension due to sorbitol content.
Contraindicated in patients with previous severe skin reactions to oseltamivir.
Known hypersensitivity reactions to formulations' excipients.
Use should be avoided in individuals with active severe liver failure without specialist supervision.
Avoid in patients with reported anaphylaxis after prior oseltamivir dosing.
Use with caution or avoid in individuals with previous neuropsychiatric adverse reactions to antiviral neuraminidase inhibitors.
Any contraindication to neuraminidase inhibitor class applies to Tamiflu unless clinical justification exists.
Contraindicated in individuals exhibiting severe renal failure if dosing cannot be appropriately adjusted.
Avoid use in infants under 1 year for prophylaxis unless directed by a specialist.
Not indicated for treatment of influenza in patients not infected with influenza virus.
Use in coordination with infectious disease specialist in patients with complex comorbidities.

Drug Interactions

Concurrent use with live attenuated influenza vaccine (FluMist) reduces vaccine effectiveness and is not recommended within 48 hours before or after Tamiflu dosing.
No significant interactions with cytochrome P450 substrates, inhibitors, or inducers due to minimal hepatic metabolism.
Co-administration with probenecid can decrease renal clearance of oseltamivir carboxylate, increasing plasma levels; clinical caution advised.
No known clinically relevant interactions with commonly used antibiotics, antipyretics, or analgesics.
Potential additive gastrointestinal adverse events when combined with other agents causing nausea or vomiting.
Limited data on interactions with immunosuppressants; cautious use recommended in immunocompromised patients.
No significant interaction reported with anticoagulants, including warfarin.
No evidence suggests interference with efficacy of systemic inactivated influenza vaccines.
No known interactions with antiretroviral agents used in HIV treatment.
No reported interactions with herbal products but patient disclosure is essential due to limited data.
Monitoring recommended when combined with other renally cleared drugs to prevent accumulation.
No evidence of interaction with commonly prescribed cardiovascular medications.
No known effect on cytochrome P450 enzymes, decreasing likelihood of drug interactions.
Concurrent use with other antiviral agents requires clinical judgment to avoid antagonistic or additive toxic effects.
Patients should inform healthcare providers of all medications to evaluate potential interactions comprehensively.

Preparations Of The Drug

Tamiflu oral capsules available in strengths of 30 mg, 45 mg, and 75 mg of oseltamivir phosphate.
Tamiflu oral suspension powder reconstituted to 6 mg/mL concentration for patients requiring liquid formulation.
Capsules are supplied in blister packs for ease of dispensing and medication adherence.
Oral suspension requires proper reconstitution with purified water; caution to dispense exact volume.
Both formulations contain inactive ingredients such as sodium lauryl sulfate, povidone, and titanium dioxide (capsules).
Liquid formulation contains sucrose and sorbitol and is not recommended in patients with hereditary fructose intolerance.
Suspension should be refrigerated after reconstitution and discarded after 17 days if unused; can be kept at room temperature for up to 10 days.
Capsules should be stored at controlled room temperature, protected from moisture and heat.
Both forms are intended for oral administration only; tampering or opening of capsules is not advised.
Packaging includes patient information leaflets and administration instructions for both treatment and prophylactic use.
Child-resistant packaging is used for safety in household settings.
Manufactured according to Good Manufacturing Practice (GMP) standards with batch consistency.
Available as brand-name product Tamiflu and as generic formulations with equivalent pharmacokinetics and efficacy.
Tamiflu is often dispensed with a dosing syringe for accurate measurement of oral suspension doses.
Shelf life varies depending on storage conditions, with usual expiration dates between 2 to 3 years from manufacture.